Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Horita, Nobuyuki ^a   Yamamoto, Masaki ^a   Sato, Takashi ^a   Tsukahara, Toshinori ^a   Nagakura, Hideyuki ^a   Tashiro, Ken ^a   Shibata, Yuji ^a   Watanabe, Hiroki ^a   Nagai, Kenjiro ^a   Inoue, Miyo ^a   Nakashima, Kentaro ^a   Ushio, Ryota ^a   Shinkai, Masaharu ^b   Kudo, Makoto ^b   Kaneko, Takeshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TOPOTECAN;

DISEASE FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMAN; META ANALYSIS; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NEOPLASM RECURRENCE, LOCAL; SMALL CELL LUNG CARCINOMA; TOPOTECAN;

EID: 84944931070     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15437     Document Type: Article

References (28)

1. Alberg A. J., Nonemaker J. Who is at high risk for lung cancer? Population-level and individual-level perspectives. Semin Respir Crit Care Med. 29, 223-32 (2008).
2. Jett, J. R., Schild, S. E., Kesler, K. A., Kalemkerian, G. P. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 143, e400S-19S (2013).
3. Asai, N., Ohkuni, Y., Kaneko, N., Yamaguchi, E., Kubo A. Relapsed small cell lung cancer: treatment options and latest developments. Ther. Adv. Med. Oncol. 6, 69-82 (2014).
4. Kim, Y. H., Mishima, M. Second-line chemotherapy for small-cell lung cancer (SCLC). Cancer Treat. Rev. 37, 143-50 (2011).
5. Hartwell, D. et al. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer Treat. Rev. 37, 242-9 (2011).
6. Ardizzoni, A., Tiseo, M., Boni L. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials. Eur. J. Cancer. 50, 2211-8 (2014).
7. Allen, J. W. et al. A randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinumtreated small-cell lung cancer. J. Clin. Oncol. 32, 2463-70 (2014).
8. Ardizzoni, A. et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J. Clin. Oncol. 15, 2090-6 (1997).
9. Eckardt, J. R. et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J. Clin. Oncol. 25, 2086-92 (2007).
10. Huber, R. M. et al. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur. Respir. J. 27, 1183-9 (2006).
11. Inoue, A. et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J. Clin. Oncol. 26, 5401-6 (2008).
12. Jotte, R. et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with smallcell lung cancer sensitive to first-line platinum-based chemotherapy. J. Clin. Oncol. 29, 287-93 (2011).
13. O'Brien, M. E. et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J. Clin. Oncol. 24, 5441-7 (2006).
14. Park, S. H. et al. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. Cancer Chemother. Pharmacol. 62, 1009-14 (2008).
15. von Pawel, J. et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. 17, 658-67 (1999).
16. von Pawel, J. et al. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J. Clin. Oncol. 19, 1743-9 (2001).
17. von Pawel, J. et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J. Clin. Oncol. 32, 4012-9 (2014).
18. Shah, C. et al. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer. 57, 84-8 (2007).
19. Spigel, D. R. et al. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer. Clin. Lung Cancer. 12, 187-91(2011).
20. Takeda, K. et al. A phase II study of topotecan in patients with relapsed small-cell lung cancer. Clin. Lung Cancer. 4, 224-8 (2003).
21. Parmar, M. K., Torri, V., Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 17, 2815-2834 (1998).
22. Higgins, P. J., Green, S. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). (2011). Available from: http://handbook.cochrane.org/frontpage.htm. Accessed on Feburary 1st, 2015.
23. Zang, J., Xiang, C., He, J. Synthesis of median survival time in meta-analysis. Epidemiology. 24, 337-8 (2013).
24. Anonymous Wilson, E. B. Probable inference, the law of succession, and statistical inference. J. Am. Stat. Assoc. 22, 209-212 (1927).
25. Higgins, J. P., Thompson, S. G., Deeks, J. J., Altman D. G. Measuring inconsistency in meta-analyses. BMJ. 327, 557-560 (2003).
26. Inomata, M. et al. Outcome and prognostic factors in patients with small cell lung cancer who receive third-line chemotherapy. Tumori. 100, 507-11 (2014).
27. Simons, D. et al. Third-line chemotherapy in small-cell lung cancer: an international analysis. Clin Lung Cancer. 15, 110-8 (2014).
28. Lara, P. N. Jr. et al. Relevance of platinum (plat) sensitivity status in previously treated extensive-stage small cell lung cancer in the modern era: A patient level analysis of SWOG trials. J. Clin. Oncol. 10, 110-115 (2015).